BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a sell rating to a hold rating in a research note issued to investors on Friday, December 29th.
NTLA has been the subject of several other research reports. Credit Suisse Group boosted their target price on Intellia Therapeutics from $24.00 to $28.00 and gave the company an outperform rating in a research report on Friday, November 3rd. ValuEngine upgraded Intellia Therapeutics from a sell rating to a hold rating in a research report on Friday, September 22nd. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the company a buy rating in a report on Tuesday, October 31st. Leerink Swann boosted their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the company an outperform rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Finally, Wedbush restated an ourperform rating and set a $25.00 target price (down previously from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $30.17.
Intellia Therapeutics (NASDAQ:NTLA) opened at $21.45 on Friday. Intellia Therapeutics has a 52-week low of $10.83 and a 52-week high of $33.34. The company has a market capitalization of $908.09 and a PE ratio of -13.84.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The firm had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $5.83 million. During the same period in the previous year, the firm posted ($0.22) earnings per share. The business’s revenue was up 49.0% compared to the same quarter last year. analysts forecast that Intellia Therapeutics will post -1.68 EPS for the current fiscal year.
In other news, CEO Nessan Bermingham sold 111,500 shares of the stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $20.34, for a total transaction of $2,267,910.00. Following the sale, the chief executive officer now directly owns 696,000 shares of the company’s stock, valued at approximately $14,156,640. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,971,283 shares of company stock worth $37,137,161 over the last ninety days. 12.80% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of NTLA. Geode Capital Management LLC lifted its stake in Intellia Therapeutics by 6.0% in the 1st quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock valued at $1,072,000 after buying an additional 4,291 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Intellia Therapeutics by 6.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 26,903 shares of the company’s stock valued at $380,000 after acquiring an additional 1,539 shares during the last quarter. Bank of America Corp DE raised its holdings in Intellia Therapeutics by 443.6% in the 1st quarter. Bank of America Corp DE now owns 17,840 shares of the company’s stock valued at $251,000 after acquiring an additional 14,558 shares during the last quarter. Bank of Montreal Can raised its holdings in Intellia Therapeutics by 1,031.7% in the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after acquiring an additional 7,222 shares during the last quarter. Finally, Rhumbline Advisers acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at about $275,000. 48.95% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/01/13/intellia-therapeutics-ntla-upgraded-at-bidaskclub.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.